Current Stem Cell Reports

, Volume 4, Issue 4, pp 273–281 | Cite as

Peripheral Blood Stem Cell Mobilization: a Look Ahead

  • Louis M. PelusEmail author
  • Hal E. Broxmeyer
In Vitro and In Vivo Models in Stem Cell Biology (E Scott, Section Editor)
Part of the following topical collections:
  1. Topical Collection on In Vitro and In Vivo Models in Stem Cell Biology


Purpose of Review

Mobilized peripheral blood is the predominant source of stem and progenitor cells for hematologic transplantation. Successful transplant requires sufficient stem cells of high enough quality to recapitulate lifelong hematopoiesis, but in some patients and normal donors, reaching critical threshold stem cell numbers is difficult to achieve. Novel strategies, particularly those offering rapid mobilization and reduced costs, remain an area of interest. This review summarizes critical scientific underpinnings in understanding the process of stem cell mobilization, with a focus on new or improved strategies for their efficient collection and engraftment.

Recent Findings

Studies are described that provide new insights into the complexity of stem cell mobilization. Agents that target new pathways such HSC egress identify strategies to collect more potent competing HSC, and new methods to optimize stem cell collection and engraftment are being evaluated.


Agents and more effective strategies that directly address the current shortcomings of hematopoietic stem cell mobilization and transplantation and offer the potential to facilitate collection and expand use of mobilized stem cells have been identified.


Peripheral blood stem cell mobilization Hematopoietic stem cells Stem cell collection HSC egress High-engrafting stem cells Hypoxic collection 



References in this review from the co-authors were supported by the National Institutes of Health Grants HL096305, AG046246, CA182947, DOD PR140433 (to LMP), and HL056416, HL112669, DK109188 HL139599, DK106846 (to HEB)

Compliance with Ethical Standards

Conflict of Interest

Louis M. Pelus and Hal E. Broxmeyer declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Panch SR, Szymanski J, Savani BN, Stroncek DF. Sources of hematopoietic stem and progenitor cells and methods to optimize yields for clinical cell therapy. Biol Blood Marrow Transplant. 2017;23(8):1241–9.PubMedGoogle Scholar
  2. 2.
    D'Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017;23(9):1417–21.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, et al. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016;51(6):778–85.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009;113(15):3604–11.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Pulsipher MA, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood. 2013;121(1):197–206.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007;40(3):185–92.PubMedGoogle Scholar
  7. 7.
    • Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, et al. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014;20(3):295–308 This provides an excellent summary of the discussion and consensus of a panel of experts to discuss data availability for peripheral blood mobilization and the transplantation of these mobilized cells. This information was used to devise guidelines for optimized mobilization. PubMedGoogle Scholar
  8. 8.
    Hosing C, Smith V, Rhodes B, Walters K, Thompson R, Qazilbash M, et al. Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation. Transfusion. 2011;51(6):1300–13.PubMedGoogle Scholar
  9. 9.
    Shaughnessy P, Chao N, Shapiro J, Walters K, McCarty J, Abhyankar S, et al. Pharmacoeconomics of hematopoietic stem cell mobilization: an overview of current evidence and gaps in the literature. Biol Blood Marrow Transplant. 2013;19(9):1301–9.PubMedGoogle Scholar
  10. 10.
    Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med. 2005;201(8):1307–18.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102(8):2728–30.PubMedGoogle Scholar
  12. 12.
    Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005;45(3):295–300.PubMedGoogle Scholar
  13. 13.
    DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767–73.PubMedGoogle Scholar
  14. 14.
    DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720–6.PubMedGoogle Scholar
  15. 15.
    Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112(4):990–8.PubMedGoogle Scholar
  16. 16.
    Pantin J, Purev E, Tian X, Cook L, Donohue-Jerussi T, Cho E, et al. Effect of high-dose plerixafor on CD34(+) cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 2017;102(3):600–9.PubMedPubMedCentralGoogle Scholar
  17. 17.
    • Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood. 2017;129(19):2680–92 This report notes that plerixafor results in rapid stem cell mobilization regardless of route of administration in clinical trials ( as no. NCT00241358 and no. NCT00914849) with a “novel” cellular graft composition and favorable recipient outcomes. PubMedPubMedCentralGoogle Scholar
  18. 18.
    Pelus LM, Bian H, King AG, Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood. 2004;103(1):110–9.PubMedGoogle Scholar
  19. 19.
    Singh P, Hu P, Hoggatt J, Moh A, Pelus LM. Expansion of bone marrow neutrophils following G-CSF administration in mice results in osteolineage cell apoptosis and mobilization of hematopoietic stem and progenitor cells. Leukemia. 2012;26(11):2375–83.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol. 2002;3(7):687–94.PubMedGoogle Scholar
  21. 21.
    Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006;12(6):657–64.PubMedGoogle Scholar
  22. 22.
    Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest. 2003;111(2):187–96.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Levesque JP, Liu F, Simmons PJ, Betsuyaku T, Senior RM, Pham C, et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood. 2004;104(1):65–72.PubMedGoogle Scholar
  24. 24.
    Richter R, Jochheim-Richter A, Ciuculescu F, Kollar K, Seifried E, Forssmann U, et al. Identification and characterization of circulating variants of CXCL12 from human plasma: effects on chemotaxis and mobilization of hematopoietic stem and progenitor cells. Stem Cells Dev. 2014;23(16):1959–74.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood. 1997;90(12):4779–88.PubMedGoogle Scholar
  26. 26.
    DeMarco SJ, Henze H, Lederer A, Moehle K, Mukherjee R, Romagnoli B, et al. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg Med Chem. 2006;14(24):8396–404.PubMedGoogle Scholar
  27. 27.
    Robinson JA, Demarco S, Gombert F, Moehle K, Obrecht D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today. 2008;13(21–22):944–51.PubMedGoogle Scholar
  28. 28.
    Karpova D, Brauninger S, Wiercinska E, Kramer A, Stock B, Graff J, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017;15(1):2.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells. 2007;25(9):2158–66.PubMedGoogle Scholar
  30. 30.
    Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, et al. The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma. Clin Cancer Res. 2014;20(2):469–79.PubMedGoogle Scholar
  31. 31.
    Peng SB, Zhang X, Paul D, Kays LM, Gough W, Stewart J, et al. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015;14(2):480–90.PubMedGoogle Scholar
  32. 32.
    Galsky MD, Vogelzang NJ, Conkling P, Raddad E, Polzer J, Roberson S, et al. A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res. 2014;20(13):3581–8.PubMedGoogle Scholar
  33. 33.
    Cho BS, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, et al. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015;126(2):222–32.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Schuster MW, Hagog N, Jalilizeinali B, Funkhauser S, Yohannan MS, Sadler J, et al. Rapid mobilization of CD34+ progenitor cells with TG0054-03, a novel CXC chemokine receptor 4 (CXCR4) antagonist. Blood. 2013;122:905.Google Scholar
  35. 35.
    Rettig MP, Ghobadi A, Holt M, Meier S, Ritchet J, Tahirovic Y, et al. ALT-1188: a new CXCR4 antagonist in development for mobilization of HSPCs. Blood. 2013;122:891.Google Scholar
  36. 36.
    Vater A, Sahlmann J, Kroger N, Zollner S, Lioznov M, Maasch C, et al. Hematopoietic stem and progenitor cell mobilization in mice and humans by a first-in-class mirror-image oligonucleotide inhibitor of CXCL12. Clin Pharmacol Ther. 2013;94(1):150–7.PubMedGoogle Scholar
  37. 37.
    Jahnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci U S A. 2010;107(47):20565–70.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Ratajczak MZ, Lee H, Wysoczynski M, Wan W, Marlicz W, Laughlin MJ, et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia. 2010;24(5):976–85.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Lee HM, Wu W, Wysoczynski M, Liu R, Zuba-Surma EK, Kucia M, et al. Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes. Leukemia. 2009;23(11):2052–62.PubMedPubMedCentralGoogle Scholar
  40. 40.
    • Adamiak M, Chelvarajan L, Lynch KR, Santos WL, Abdel-Latif A, Ratajczak MZ. Mobilization studies in mice deficient in sphingosine kinase 2 support a crucial role of the plasma level of sphingosine-1-phosphate in the egress of hematopoietic stem progenitor cells. Oncotarget. 2017;8(39):65588–600 The results provide support for a role for S1P gradients in blood plasma during the mobilization process and suggest that small-molecule inhibitors of sphingosine kinase 2 and S1P-degrading enzyme S1P lyase could be used as compounds that might facilitate mobilization of HSPCs. PubMedPubMedCentralGoogle Scholar
  41. 41.
    Juarez JG, Harun N, Thien M, Welschinger R, Baraz R, Pena AD, et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood. 2012;119(3):707–16.PubMedGoogle Scholar
  42. 42.
    Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012;26(1):34–53.PubMedGoogle Scholar
  43. 43.
    Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood. 2009;114(7):1340–3.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Hoggatt J, Speth JM, Pelus LM. Concise review: sowing the seeds of a fruitful harvest: hematopoietic stem cell mobilization. Stem Cells. 2013;31(12):2599–606.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Di GF, Lewandowski D, Cabannes E, Nancy-Portebois V, Petitou M, Fichelson S, et al. Heparan sulfate mimetics can efficiently mobilize long-term hematopoietic stem cells. Haematologica. 2012;97(4):491–9.Google Scholar
  46. 46.
    • Kook S, Cho J, Lee SB, Lee BC. The nucleotide sugar UDP-glucose mobilizes long-term repopulating primitive hematopoietic cells. J Clin Invest. 2013;123(8):3420–35 This study demonstrates that a nucleotide sugar, UDP-glucose, which is released into extracellular fluids in stress can mobilize HSC and HPC. This might provide an alternative strategy to improve the yields of HSPCs in poorly mobilizing allogeneic and autologous donors. PubMedPubMedCentralGoogle Scholar
  47. 47.
    Niesvizky R, Mark TM, Ward M, Jayabalan DS, Pearse RN, Manco M, et al. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res. 2013;19(6):1534–46.PubMedPubMedCentralGoogle Scholar
  48. 48.
    •• Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, et al. Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature. 2013;495(7441):365–9 Prostaglandin (PGE)2 is a regulator of hematopoiesis and enhance HSC expansion. This study demonstrates that inhibition of endogenous PGE2 by non-steroidal anti-inflammatory drugs (NSAIDs) results in egress in HSC from mouse bone marrow through E-prostanoid 4 (EP4) receptor signaling, effects confirmed in non-human primates and healthy human volunteers, and that grafts mobilized with NSAIDS had superior repopulating ability and long-term engraftment capability. PubMedPubMedCentralGoogle Scholar
  49. 49.
    Jeker B, Novak U, Mansouri TB, Baerlocher GM, Seipel K, Mueller BU, et al. NSAID treatment with meloxicam enhances peripheral stem cell mobilization in myeloma. Bone Marrow Transplant. 2018;53(2):175–9.PubMedGoogle Scholar
  50. 50.
    Barrett AJ, Longhurst P, Sneath P, Watson JG. Mobilization of CFU-C by exercise and ACTH induced stress in man. Exp Hematol. 1978;6(7):590–4.PubMedGoogle Scholar
  51. 51.
    Katayama Y, Battista M, Kao WM, Hidalgo A, Peired AJ, Thomas SA, et al. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. Cell. 2006;124(2):407–21.Google Scholar
  52. 52.
    • Lucas D, Bruns I, Battista M, Mendez-Ferrer S, Magnon C, Kunisaki Y, et al. Norepinephrine reuptake inhibition promotes mobilization in mice: potential impact to rescue low stem cell yields. Blood. 2012;119(17):3962–5 It was previously reported by this group that G-CSF induced mobilization of hematopoietic stem cells (HSCs) was controlled by peripheral sympathetic nerves via signaling of norepinephrine (NE). The main point of this paper is that blockage of NE reuptake has the potential to serve as a novel therapeutic target to increase yields of HSCs in patients. PubMedPubMedCentralGoogle Scholar
  53. 53.
    Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829–34.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Mendez-Ferrer S, Battista M, Frenette PS. Cooperation of beta(2)- and beta(3)-adrenergic receptors in hematopoietic progenitor cell mobilization. Ann N Y Acad Sci. 2010;1192:139–44.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Hopman RK, DiPersio JF. Advances in stem cell mobilization. Blood Rev. 2014;28(1):31–40.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Domingues MJ, Nilsson SK, Cao B. New agents in HSC mobilization. Int J Hematol. 2017;105(2):141–52.PubMedGoogle Scholar
  57. 57.
    Ratajczak MZ, Suszynska M. Emerging strategies to enhance homing and engraftment of hematopoietic stem cells. Stem Cell Rev. 2016;12(1):121–8.PubMedGoogle Scholar
  58. 58.
    Bendall L. Extracellular molecules in hematopoietic stem cell mobilisation. Int J Hematol. 2017;105(2):118–28.PubMedGoogle Scholar
  59. 59.
    Yosupov N, Haimov H, Juodzbalys G. Mobilization, isolation and characterization of stem cells from peripheral blood: a systematic review. J Oral Maxillofac Res. 2017;8(1):e1.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Christopherson KW, Cooper S, Hangoc G, Broxmeyer HE. CD26 is essential for normal G-CSF-induced progenitor cell mobilization as determined by CD26−/− mice. Exp Hematol. 2003;31(11):1126–34.PubMedGoogle Scholar
  61. 61.
    Christopherson KW, Cooper S, Broxmeyer HE. Cell surface peptidase CD26/DPPIV mediates G-CSF mobilization of mouse progenitor cells. Blood. 2003;101(12):4680–6.PubMedGoogle Scholar
  62. 62.
    Christopherson KW, Hangoc G, Broxmeyer HE. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells. J Immunol. 2002;169(12):7000–8.PubMedGoogle Scholar
  63. 63.
    •• Singh P, Hoggatt J, Kamocka MM, Mohammad KS, Saunders MR, Li H, et al. Neuropeptide Y regulates a vascular gateway for hematopoietic stem and progenitor cells. J Clin Invest. 2017;127(12):4527–40 This report defines ECs as gatekeepers of the trafficking of HSCs/HPCs and mechanistically identified a CD26-mediated neutrotransmitter neuropeptide Y axis with the potential to pharmacologically target trafficking of HSCs/HPCs in homeostasis and during stress. PubMedPubMedCentralGoogle Scholar
  64. 64.
    Itkin T, Gur-Cohen S, Spencer JA, Schajnovitz A, Ramasamy SK, Kusumbe AP, et al. Distinct bone marrow blood vessels differentially regulate haematopoiesis. Nature. 2016;532(7599):323–8.Google Scholar
  65. 65.
    Bedoui S, Lechner S, Gebhardt T, Nave H, Beck-Sickinger AG, Straub RH, et al. NPY modulates epinephrine-induced leukocytosis via Y-1 and Y-5 receptor activation in vivo: sympathetic co-transmission during leukocyte mobilization. J Neuroimmunol. 2002;132(1–2):25–33.PubMedGoogle Scholar
  66. 66.
    Straub RH, Schaller T, Miller LE, von HS, Jessop DS, Falk W, et al. Neuropeptide Y cotransmission with norepinephrine in the sympathetic nerve-macrophage interplay. J Neurochem. 2000;75(6):2464–71.PubMedGoogle Scholar
  67. 67.
    Ekblad E, Edvinsson L, Wahlestedt C, Uddman R, Hakanson R, Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept. 1984;8(3):225–35.PubMedGoogle Scholar
  68. 68.
    Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res. 1998;83(2):187–95.PubMedGoogle Scholar
  69. 69.
    King AG, Horowitz D, Dillon SB, Levin R, Farese AM, MacVittie TJ, et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRObeta. Blood. 2001;97(6):1534–42.PubMedGoogle Scholar
  70. 70.
    •• Hoggatt J, Singh P, Tate TA, Chou BK, Datari SR, Fukuda S, et al. Rapid mobilization reveals a highly engraftable hematopoietic stem cell. Cell. 2018;172(1–2):191–204 The CXCR2 agonist GROβ in combination with the CXCR4 antagonist AMD3100/plerixafor mobilize HSCs within hours rather than days needed for G-CSF. This effect occurs through synergistic signaling on neutrophils and leads to mobilization of HSC with more potent engraftment capacity. PubMedGoogle Scholar
  71. 71.
    Pruijt JF, Fibbe WE, Laterveer L, Pieters RA, Lindley IJ, Paemen L, et al. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci U S A. 1999;96(19):10863–8.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Fukuda S, Bian H, King AG, Pelus LM. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood. 2007;110(3):860–9.PubMedPubMedCentralGoogle Scholar
  73. 73.
    Broxmeyer HE, Orazi A, Hague NL, Sledge GW Jr, Rasmussen H, Gordon MS. Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer. Blood Cells Mol Dis. 1998;24(1):14–30.PubMedGoogle Scholar
  74. 74.
    Merzouk A, Wong D, Salari H, Bian H, Fukuda S, Pelus LM. Rational design of chemokine SDF-1 analogs with agonist activity for the CXCR4 receptor and the capacity to rapidly mobilize PMN and hematopoietic progenitor cells in mice. Lett Drug Des Discov. 2004;1:126–34.Google Scholar
  75. 75.
    Pelus LM, Bian H, Fukuda S, Wong D, Merzouk A, Salari H. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Exp Hematol. 2005;33(3):295–307.PubMedGoogle Scholar
  76. 76.
    Hoggatt J, Pelus LM. Hematopoietic stem cell mobilization with agents other than G-CSF. In: Kolonin MG, Simmons PJ, editors. Stem cell mobilization; methods and protocols. New York: Springer; 2012. p. 49–67.Google Scholar
  77. 77.
    Broxmeyer HE, Cooper S, Lasky LA, De SF. Identification of a massive reserve of hematopoietic progenitors in mice. Stem Cells Dev. 2005;14(2):105–10.PubMedGoogle Scholar
  78. 78.
    Broxmeyer HE, Van ZG, Schultz EF, Koltun LA, LoBue J, Gordon AS. Glass wool separation of rat polymorphonuclear leukocytes according to adherence and maturity. J Reticuloendothel Soc. 1975;18(2):118–24.PubMedGoogle Scholar
  79. 79.
    Broxmeyer HE, O’Leary HA, Huang X, Mantel C. The importance of hypoxia and extra physiologic oxygen shock/stress for collection and processing of stem and progenitor cells to understand true physiology/pathology of these cells ex vivo. Curr Opin Hematol. 2015;22(4):273–8.PubMedPubMedCentralGoogle Scholar
  80. 80.
    •• Mantel CR, O’Leary HA, Chitteti BR, Huang X, Cooper S, Hangoc G, et al. Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock. Cell. 2015;161(7):1553–65 This study demonstrates that there are more hematopoietic stem cells (HSCs) in mouse bone marrow and human cord blood than previously realized, and that ablating the phenomenon of extra physiologic oxygen shock stress (EPHOSS) by collecting and processing cells in low oxygen (3%), one can collect two to five times more HSCs. PubMedPubMedCentralGoogle Scholar
  81. 81.
    Cai Q, Capitano M, Huang X, Guo B, Cooper S, Broxmeyer HE. Combinations of antioxidants and/or of epigenetic enzyme inhibitors allow for enhanced collection of mouse bone marrow hematopoietic stem cells in ambient air. Blood Cells Mol Dis. 2018;71:23–8.PubMedGoogle Scholar
  82. 82.
    •• Broxmeyer HE, Hoggatt J, O'Leary HA, Mantel C, Chitteti BR, Cooper S, et al. Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis. Nat Med. 2012;18(12):1786–96 Cell surface dipeptidylpeptidase (DPP)4/CD26 was found to truncate and decrease the activities of GM-CSF, IL-3 and SDF-1/CXCL12. By inhibiting the DPP4 activity with small molecules such as diprotin A (ILE-PRO-ILE) or sitagliptin/Januvia, one can enhance the functional activities of GM-CSF, IL-3, and SDF-1 and enhance recovery of stressed hematopoiesis. PubMedPubMedCentralGoogle Scholar
  83. 83.
    Christopherson KW, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305(5686):1000–3.PubMedGoogle Scholar
  84. 84.
    Hoggatt J, Singh P, Sampath J, Pelus LM. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood. 2009;113(22):5444–55.PubMedPubMedCentralGoogle Scholar
  85. 85.
    North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447(7147):1007–11.PubMedPubMedCentralGoogle Scholar
  86. 86.
    • Guo B, Huang X, Cooper S, Broxmeyer HE. Glucocorticoid hormone-induced chromatin remodeling enhances human hematopoietic stem cell homing and engraftment. Nat Med. 2017;23(4):424–8 This paper reports the identification of glucocorticoid (GC) hormone signaling as an activator of CXCR4 expression on human cord blood (CB) HSCs and HPCs, mediated by activated glucocorticoid receptor binding with the glucocorticoid response element in the CXCR4 promoter and recruitment of the SRC-1-p300 complex promoting H4K5 and H4K6 histone acetylation resulting in enhanced engraftment of short-term treated human CB in immune deficient mice. PubMedPubMedCentralGoogle Scholar
  87. 87.
    • Huang XX, Guo B, Broxmeyer HE. Neutralizing negative epigenetic regulation by HDAC5 enhances human hematopoietic stem cell homing and engraftment. Nat Commun 2018; 9(1):2741. This report provides additional means to enhance the expression of CXCR4 on human cord blood hematopoietic stem cells (HSCs) and their engraftment in immune-deficient mice. Inhibition of HDAC5 increased acetylated p65 levels in the nucleus, with activation of the NF-κB signaling pathway via TNF-α, important for enhancing the homing and engraftment of mobilized peripheral blood HSCs. Google Scholar
  88. 88.
    Capitano ML, Hangoc G, Cooper S, Broxmeyer HE. Mild heat treatment primes human CD34(+) cord blood cells for migration toward SDF-1alpha and enhances engraftment in an NSG mouse model. Stem Cells. 2015;33(6):1975–84.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013;122(17):3074–81.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Farag SS, Srivastava S, Messina-Graham S, Schwartz J, Robertson MJ, Abonour R, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev. 2013;22(7):1007–15.PubMedGoogle Scholar
  91. 91.
    Farag SS, Nelson R, Cairo MS, O'Leary HA, Zhang S, Huntley C, et al. High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation. Oncotarget. 2017;8(66):110350–7.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Genovese P, Schiroli G, Escobar G, Tomaso TD, Firrito C, Calabria A, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 2014;510(7504):235–40.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Barwinska D, Oueini H, Poirier C, Albrecht M, Bogatcheva N, Justice M et al. AMD3100 ameliorates cigarette smoke-induced emphysema-like manifestations in mice. Amer J Physiol Lung Cell Molec Physiology, 2018 May 10. [Epub ahead of print], 315, L382, L386.PubMedGoogle Scholar
  94. 94.
    Humbert O, Chan F, Rajawat YS, Torgerson TR, Burtner CR, Hubbard NW, et al. Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy. Blood Adv. 2018;2(9):987–99.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Department of Microbiology & ImmunologyIndiana University School of MedicineIndianapolisUSA

Personalised recommendations